ASTH Stock Astrana Health (ASTH, $30.33) Moving Average Convergence Divergence (MACD) Histogram turned positive on October 7, 2025

GET DAILY SIGNALS

Get AI intraday signals

ASTH - Astrana Health

MACD signal

View

Odds of UP Trend

Price: $30.33

Daily change: +$1.46 (+5.06%)

Daily volume: 420.9K

Capitalization: $1.4B

Industry: Hospital/Nursing Management

ASTH in upward trend: price rose above 50-day moving average on October 03, 2025

ASTH moved above its 50-day moving average on October 03, 2025 date and that indicates a change from a downward trend to an upward trend. In of 31 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 03, 2025. You may want to consider a long position or call options on ASTH as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ASTH just turned positive on October 07, 2025. Looking at past instances where ASTH's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ASTH advanced for three days, in of 325 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ASTH moved out of overbought territory on September 03, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASTH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ASTH broke above its upper Bollinger Band on October 07, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ASTH entered a downward trend on October 01, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ASTH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.788) is normal, around the industry mean (6.064). P/E Ratio (57.019) is within average values for comparable stocks, (115.975). ASTH's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.001). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (0.596) is also within normal values, averaging (1.527).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ASTH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.